Targeting KRAS in Lung Cancer: Current Status and Future Directions

Dear Colleagues,

The Special Issue aims to provide a comprehensive overview of the latest advances and challenges in targeting KRAS-driven lung cancers. KRAS mutations are among the most common oncogenic drivers in non-small cell lung cancer (NSCLC), yet they have historically posed significant therapeutic challenges. With the recent approval of KRAS G12C inhibitors and ongoing development of novel therapeutic strategies, this issue seeks to explore the evolving landscape of KRAS-targeted therapies in both early and advanced disease settings. Topics of interest include molecular diagnostics, mechanism-based therapeutics, resistance mechanisms, combination therapies, and real-world clinical outcomes. We also welcome contributions on biomarker development, translational research, and innovative trial designs that may shape future directions in KRAS-mutant lung cancer management. This issue emphasizes stage-dependent treatment strategies, molecular characterization, and the integration of systemic therapies to improve patient survival and quality of life.

Dr. Sally Lau
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Current Oncology is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.